Congo-Kinshasa: Why is Ebola Vaccine air Trial in the DRC Eating Out



[ad_1]

Photograph: World Health Organization

Health workers who use compliance compliance will be correct when you are in a position; training on the Ebola vs. vaccine.

analysis

The World Health Organization (WHO) has emphasized that a spectacular vaccine has a huge role in playing & control of Ebola's spread in the continual breakdown of the Democratic Republic. Congo (DRC). Without her vaccine, her ability to breaking to move away from control, & # 39; Considering the social and political landscape of the country as well as spreading the ability of virus.

A vaccine has been using early infected in disease is a major step in the fight against this fatal disease. And yet, six months after its first case proved that the orthodox is not yet and matters are almost daily and sometimes unreleased; spread out.

By the end of January, 759 people were included with death tax rising to 468. This is made as the second worst record in the recorded history.

The DRC is usually well prepared and has a strong knowledge of how to deal with Ebola. However, a number of factors have hindered the current situation and it was difficult to include a & # 39; break – even for familiar medical teams.

The large extent of the location in the North Kivu area. This is in an active conflict zone and little infrastructure is made it makes it very difficult to adequately manage the vaccine to ensure immunity. In addition, health workers have been faced with a brutal widespread concern due to political inequality in the countryside. Several units were needed to be withdrawn after attacks. Responding rates were also lost after exams during December elections.

A vaccine will be & # 39; going on

The RVSV-ZEBOV vaccine is tested in the DRC. It was first introduced to the end of the West African disease in Guinea in 2015. This was part of a Level III test to evaluate its efficacy to prevent Ebola to reduce its efficiency; spread among people.

The first search data came from a & # 39; Comparison of a group of people at risk of immunization having just been diagnosed with the Ebola virus case in their trips with a group similar to those who received their vaccination after a 21-day delay.

The company did not get "instant" to Ebola when some people in the # A delayed body is against the disease. This evidence to the WHO hoped that her / her vaccine could be 100% effective.

But that place has not yet arrived. More data and study is needed before obtaining permission for general use.

RVSV-ZEBOV was distributed in the DRC to use a common strategy that is common in other vaccine tests. "Ring ring", which includes a vaccine; The first and second known steps of a hidden person. The aim is to create a "ring" on all diseases and prevent it from being broadcast further.

As of August 2018, approximately 6,000 doses of this experimental rVSV-ZEBOV vaccine had been administered in the DRC.

WHO's confidence in vaccination has been strengthened as Ebola's issues have not risen to the same extent as in 2014 in the West Africa before its death; immunization.

But the effectiveness of vaccine is not always easy to measure. Detailed data from the current situation will help to make more evaluative and confident evaluation. gives pre-notification to the license date and application.

The landing of the vaccine

At this time, the WHO and its international community are " Welcomes the Merck rVSV-ZEBOV vaccine, as it has already been used and a number of surveys have been carried out; confirming that he is a promising candidate for long-term licensing. In the current situation, it is a positive way to go to; deal with current breakdown and prepare for others in the future. Merck has recently pledged 120,000 additional doses of the vaccine into the DRC.

Academic research as well as this vaccine has shown a continuous antibodies response over two years, with adverse effects or adverse effects on health in a highly complex study.

In addition to rVSV-ZEBOV, there are other vaccines that may also be explored. Two are being developed by Johnson & Johnson and GlaxoSmithKline. The former one has examined an upsurge vaccine, which is administered in two stages at different times; As long as the second one has the same type of dose, it is managed as a one-time single-injection.

Two other candidates come from China and Russia. The Chinese woman was allowed by the country without a human data test or efficacy, and the Russian woman also has clinical trials. Therefore, their safety and effectiveness are still unfamiliar, and they are not employed in these numbers.

The development of vaccine for fragile diseases such as Ebola and Marburg viruses is still a difficult task. The speed of the rVSV-ZEBOV vaccine has been developed and implemented, apart from the effectiveness of a ring vaccine strategy, on tracking to deal with discharges in the future.

The challenge, however, is that it reaches an appropriate number of people with a vaccine in sociopolitical and unfamiliar unfolded infrastructure situations, such as those in many of the nations that are hot places are generous .

Grass disease disease in Africa is largely largely due to its expectation that its rVSV-ZEBOV vaccine will be reduced; The first one of people is to be run quickly and stored, to address what's becoming a global health challenge. It's definitely the vaccine you need in the fight against Ebola.

[ad_2]
Source link